Cellectar Biosciences (CLRB) Current Deferred Revenue (2017 - 2018)
Cellectar Biosciences (CLRB) posted Current Deferred Revenue of $33090.0 for Q4 2018, down 18.17% sequentially from $40438.0 in Q2 2018, and down 76.18% YoY from $138944.0 in Q4 2017.
Cellectar Biosciences (CLRB) Current Deferred Revenue (2017 - 2018) Analysis & Trends
Cellectar Biosciences has reported Current Deferred Revenue for 2 years, with the latest figure at $33090.0 in Q4 2018.
- Quarterly Current Deferred Revenue fell 76.18% year-over-year to $33090.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $33090.0 (down 76.18% YoY) and the FY2018 annual result came in at $33090.0, down 76.18% from the prior year.
- Current Deferred Revenue fell to $33090.0 in Q4 2018 per CLRB's latest filing, from $40438.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $138944.0 in Q4 2017 and troughed at $33090.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 33,090.00 |
| Jun 30, 2018 | 40,438.00 |
| Mar 31, 2018 | 88,964.00 |
| Dec 31, 2017 | 138,944.00 |